Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lobeline is a piperidine alkaloid found in several plants of the Lobelia genus, including Indian tobacco (Lobelia inflata). It has been used historically as a smoking cessation aid and for respiratory disorders, though clinical evidence supporting its efficacy is limited. Lobeline acts primarily as a ligand at the vesicular monoamine transporter 2 (VMAT2), inhibiting dopamine uptake and promoting dopamine release from storage vesicles within presynaptic terminals. It also inhibits reuptake of dopamine and serotonin, functions as a mixed agonist–antagonist at nicotinic acetylcholine receptors (notably α3β2 and α4β2 subtypes), antagonizes μ-opioid receptors, and may inhibit P-glycoprotein. These mechanisms underlie its potential to modulate neurochemical pathways involved in addiction and neurodegenerative diseases such as Parkinson's disease. Despite preclinical promise for treating drug dependence (nicotine, amphetamines) and possible neuroprotective effects, there is little robust clinical evidence for approved therapeutic use[1][3][5][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lobeline.